CCL21 is an effective surgical neoadjuvant for treatment of mammary tumors.

Abdelkader E. Ashour, Xuede Lin, Xiaojian Wang, Heth R. Turnquist, Nicole M. Burns, Amit Tuli, Anguraj Sadanandam, Khaled Suleiman, Rakesh K. Singh, James E. Talmadge, Joyce C. Solheim

Research output: Contribution to journalArticlepeer-review

8 Scopus citations

Abstract

In previous studies, the chemokine CCL21 has shown biological activities that include T cell, natural killer (NK) cell, and dendritic cell (DC) chemoattraction. The goal of this study was to determine the effects of administering CCL21 to orthotopic mammary tumors in terms of impact on tumor growth rate, immune cell infiltration of the primary tumor and survival. We found that a single intratumoral administration of CCL21 slowed the growth of orthotopic mammary tumors and increased intratumoral infiltration by T cells, NK cells and DCs. CCL21 intratumoral administration also prolonged the survival of tumor-earing mice. Furthermore, mice that received intratumoral neoadjuvant CCL21 ior to surgical resection of tumors survived significantly longer than control mice. The urviving neoadjuvant CCL21-reated mice, when challenged again with cl-6, had significantly slower rate of tumor growth than challenged control mice. Thus, our ata indicate that CCL21 treatment prior to mammary tumor resection can significantly rolong survival and increase resistance to subsequent tumor challenge. Overall, our indings suggest that intratumoral administration of CCL21 has potential as a neoadjuvant mmunotherapy for breast cancer.

Original languageEnglish (US)
Pages (from-to)1206-1210
Number of pages5
JournalCancer biology & therapy
Volume6
Issue number8
StatePublished - Aug 2007

ASJC Scopus subject areas

  • Molecular Medicine
  • Oncology
  • Pharmacology
  • Cancer Research

Fingerprint

Dive into the research topics of 'CCL21 is an effective surgical neoadjuvant for treatment of mammary tumors.'. Together they form a unique fingerprint.

Cite this